Prnewswire·2025-12-09 11:55Core Insights - Fosun Pharma's subsidiary Yao Pharma has entered into an exclusive collaboration and license agreement with Pfizer for the development and commercialization of oral small-molecule GLP-1R agonists, including YP05002 [1][2] - Yao Pharma will receive an upfront payment of $150 million and potential milestone payments up to $1.935 billion, along with tiered royalties on sales if approved [1] - The partnership is seen as a significant milestone in Fosun Pharma's strategy of innovation and internationalization, aiming to address unmet clinical needs in metabolic diseases [3] Company Overview - Yao Pharma has developed small-molecule GLP-1R agonists with proprietary intellectual property rights, targeting metabolic diseases such as chronic weight management, type 2 diabetes, and non-alcoholic steatohepatitis (NASH) [2] - YP05002 is currently in Phase 1 clinical development in Australia, indicating progress in the drug's development pipeline [2] Strategic Implications - The collaboration with Pfizer is viewed as a recognition of Yao Pharma's R&D capabilities and aims to leverage Pfizer's global development experience to expedite the commercialization of YP05002 [3] - Fosun Pharma's leadership emphasizes the importance of collaboration in maximizing the value of innovation and addressing global health challenges related to obesity and metabolic diseases [3]